Core Viewpoint - Federal Pharmaceutical (03933) shares rose over 8% following a positive earnings forecast, with a current price of HKD 17.62 and a trading volume of HKD 598 million [1] Financial Performance - The company anticipates a net profit of approximately RMB 1.85 billion for the six months ending June 30, 2025, compared to a net profit of about RMB 1.491 billion for the same period ending June 30, 2024 [1] - The increase in net profit is primarily attributed to licensing fee income from Novo Nordisk, amounting to approximately RMB 1.1 billion [1] Segment Performance - Despite the overall profit increase, the intermediate product segment's profit decreased by approximately RMB 430 million, and the raw material drug segment's profit declined by about RMB 270 million, partially offsetting the growth [1]
港股异动 | 联邦制药(03933)盈喜后涨超8% 预期中期净溢利约为18.5亿元